24th Sep 2021 07:00
Notice of Preliminary Results
Oxford, UK; 24 September 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the ethical clinical AI company, will announce its Preliminary Results for the 12 months ended 30 April 2021 on Friday, 1st October.
Lord (Paul) Drayson, Chief Executive Officer, and Richard Pye, Chief Financial Officer, will host a virtual briefing for analysts and investors at 13:00 GMT / 08:00 ET on the day of the results.
Details of the webcast, and the presentation slides, will be available via the Company's website. For more details, please contact [email protected].
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson PhD FREng, Chief Executive Officer |
|
Dr Richard Pye, Chief Financial Officer |
|
Peel Hunt LLP (Nominated Adviser and Joint Broker) | + 44 (0) 20 7418 8900 |
Dr Christopher Golden |
|
James Steel |
|
Oliver Jackson |
|
Liberum (Joint Broker) | + 44 (0) 20 3100 2000 |
Bidhi Bhoma |
|
Euan Brown |
|
Consilium Strategic Communications | +44 (0) 7780600290 |
Mary-Jane Elliott |
|
Jessica Hodgson |
|
Davide Salvi |
|
|
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with global healthcare organisations to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com
Related Shares:
SENS.L